CY1119430T1 - Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινου - Google Patents
Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινουInfo
- Publication number
- CY1119430T1 CY1119430T1 CY20171100909T CY171100909T CY1119430T1 CY 1119430 T1 CY1119430 T1 CY 1119430T1 CY 20171100909 T CY20171100909 T CY 20171100909T CY 171100909 T CY171100909 T CY 171100909T CY 1119430 T1 CY1119430 T1 CY 1119430T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- treatment
- cancer diagnosis
- relates
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με τη χρήση αντισωμάτων έναντι της πρωτεΐνης S100A7 για την πρόληψη ή/και θεραπευτική αγωγή καρκίνου ή ασθένειας που σχετίζεται με ανεπιθύμητη αγγειογένεση ή ασθένειας που σχετίζεται με φλεγμονή, και με μεθόδους και κιτ για τη διάγνωση και τον προσδιορισμό της προγνωστικότητας των εν λόγω ασθενειών in vitro και in vivo μέσω ανίχνευσης των επιπέδων S100Α7 σε ένα βιορευστό, κατά προτίμηση με ένα αντίσωμα. Η εφεύρεση αναφέρεται επίσης σε ειδικά αντι-S100A7 μονοκλωνικά αντισώματα, σε υβριδωματικές κυτταρικές σειρές που τα παράγουν και σε μέθοδο για την απόκτηση αυτών, καθώς επίσης σε φαρμακευτικές συνθέσεις και συζεύγματα που τα περιέχουν.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382128 | 2013-04-09 | ||
EP14723729.1A EP2984108B1 (en) | 2013-04-09 | 2014-04-09 | Anti-s100a7 antibodies for the treatment and diagnosis of cancer |
PCT/EP2014/057213 WO2014167030A1 (en) | 2013-04-09 | 2014-04-09 | Anti-s100a7 antibodies for the treatment and diagnosis of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119430T1 true CY1119430T1 (el) | 2018-03-07 |
Family
ID=48049929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100909T CY1119430T1 (el) | 2013-04-09 | 2017-08-30 | Anti-s100a7 αντισωματα για τη θεραπευτικη αγωγη και διαγνωση καρκινου |
Country Status (10)
Country | Link |
---|---|
US (1) | US9914768B2 (el) |
EP (1) | EP2984108B1 (el) |
CN (1) | CN105873950A (el) |
CY (1) | CY1119430T1 (el) |
DK (1) | DK2984108T3 (el) |
ES (1) | ES2639227T3 (el) |
LT (1) | LT2984108T (el) |
PL (1) | PL2984108T3 (el) |
PT (1) | PT2984108T (el) |
WO (1) | WO2014167030A1 (el) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2784946T3 (es) * | 2016-03-14 | 2020-10-02 | Somalogic Inc | Compuestos y métodos para la síntesis de 5-(triptaminocarboxiamida n-protegida)-2'-desoxiuridina fosforamidita para su incorporación a una secuencia de ácido nucleico |
KR102645432B1 (ko) * | 2016-03-28 | 2024-03-11 | (주)아모레퍼시픽 | 피부 세포 분화 촉진용 조성물 및 피부 세포 분화 촉진 물질의 스크리닝 방법 |
CN106943594A (zh) * | 2017-03-29 | 2017-07-14 | 西安交通大学 | Psoriasin抗体和LL‑37抗体在制备防治银屑病的药物中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
CA2472163C (en) | 2001-12-31 | 2012-12-18 | Dana-Farber Cancer Institute, Inc. | Psoriasin expression by breast epithelial cells |
US20100021472A1 (en) | 2008-07-25 | 2010-01-28 | Geetha Srikrishna | Methods for diagnosing and treating cancer |
EP2580240B1 (en) | 2010-06-14 | 2018-11-28 | Lykera Biomed S.A. | S100a4 antibodies and therapeutic uses thereof |
-
2014
- 2014-04-09 EP EP14723729.1A patent/EP2984108B1/en active Active
- 2014-04-09 ES ES14723729.1T patent/ES2639227T3/es active Active
- 2014-04-09 WO PCT/EP2014/057213 patent/WO2014167030A1/en active Application Filing
- 2014-04-09 LT LTEP14723729.1T patent/LT2984108T/lt unknown
- 2014-04-09 CN CN201480032964.2A patent/CN105873950A/zh active Pending
- 2014-04-09 DK DK14723729.1T patent/DK2984108T3/en active
- 2014-04-09 PT PT147237291T patent/PT2984108T/pt unknown
- 2014-04-09 US US14/897,108 patent/US9914768B2/en active Active
- 2014-04-09 PL PL14723729T patent/PL2984108T3/pl unknown
-
2017
- 2017-08-30 CY CY20171100909T patent/CY1119430T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN105873950A (zh) | 2016-08-17 |
LT2984108T (lt) | 2017-11-10 |
WO2014167030A1 (en) | 2014-10-16 |
DK2984108T3 (en) | 2017-09-18 |
PT2984108T (pt) | 2017-09-19 |
US9914768B2 (en) | 2018-03-13 |
EP2984108B1 (en) | 2017-05-31 |
PL2984108T3 (pl) | 2017-12-29 |
EP2984108A1 (en) | 2016-02-17 |
US20160289307A1 (en) | 2016-10-06 |
ES2639227T3 (es) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1120359T1 (el) | Σταθερες φαρμακοτεχνικες μορφες αντισωματων εναντι ανθρωπινου υποδοχεα pd-1 προγραμματισμενου θανατου και σχετικες θεραπειες | |
CY1123435T1 (el) | Anti-pd-l1 αντισωματα και χρησεις αυτων | |
CY1123028T1 (el) | Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf | |
CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
CY1124435T1 (el) | Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α | |
UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
UA117364C2 (uk) | Похідні аматоксину | |
TN2015000396A1 (en) | Antibody drug conjugates | |
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
BR112013021350A2 (pt) | anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes | |
EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
CY1122156T1 (el) | Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων | |
BR112016008146A2 (pt) | Anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos para detectar um câncer, de identificação e de seleção de um paciente com câncer | |
CY1123743T1 (el) | Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου | |
EA201690388A1 (ru) | Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов | |
EA201992316A1 (ru) | Композиции и способы для диагностики рака предстательной железы |